The DOI matches its Crossref record; 416 of the 416 references it cites were found in a registry or an index.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Abstract
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–416 of 416
Christiansen, M. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/003655101300133649 · Cited by 33
Shaffer, D. R., Viale, A. J., Ishiwata, R., Leversha, M. A., Olgac, S., Manova, K., Satagopan, J. M., Scher, H. I., & Koff, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407362102 · Cited by 31
Role of prostate-specific antigen as a predictor of outcome in prostate cancer
Blackledge, G. R. P., & Lowery, K. (1994) · The Prostate · doi:10.1002/pros.2990250710 · Cited by 31
Bruun, L., Becker, C., Hugosson, J., Lilja, H. G., & Christensson, A. G. (2005) · The Prostate · doi:10.1002/pros.20286 · Cited by 31
Self-citationRobertson, D. M., Pruysers, E., Burger, H., et al. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.02.014 · Cited by 29
Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer
Kurlender, L., Yousef, G. M., Memari, N., et al. (2004) · Tumor Biology · doi:10.1159/000079147 · Cited by 29
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Tveit, K. M., & Kataja, V. V. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi827 · Cited by 29
Screening tests for colorectal cancer: A menu of options remains relevant
Allison, J. E., & Lawson, M. J. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0079-4 · Cited by 25
Vasey, P. A., Herrstedt, J., & Jelić, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi823 · Cited by 25
Aschele, C., Debernardis, D., Lonardi, S., Bandelloni, R., Casazza, S., Monfardini, S., & Gallo, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.066 · Cited by 25
Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer
El-Rayes, B. F., Shields, A. F., Vaishampayan, U. N., Heilbrun, L. K., Bekaii‐Saab, T., Zalupski, M. M., & Philip, P. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3766 · Cited by 21
Faecal screening of colorectal cancer
Loganayagam, A. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01532.x · Cited by 14
Watine, J., & Friedberg, B. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.02.017 · Cited by 14
Rissanen, M., Helo, P., Väänänen, R., Wahlroos, V., Lilja, H. G., Nurmi, M. J., Pettersson, K. S. I., & Nurmi, J. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.10.005 · Cited by 12
Self-citationIs Acid Phosphatase (PAP) Still Justified in the Management of Prostatic Cancer?
Kontturi, M. J. (1991) · Acta Oncologica · doi:10.3109/02841869109092343 · Cited by 11
Keller, T., Butz, H., Lein, M., Kwiatkowski, M., Semjonow, A., Luboldt, H., Hammerer, P., Stephan, C., & Jung, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039552 · Cited by 9
Self-citation
Cited by
Practice Parameters for the Management of Rectal Cancer (Revised)
Monson, J. R. T., Weiser, M. R., Buie, W. D., Chang, G. J., Rafferty, J. F., Buie, W. D., Rafferty, J., Guillem, J., Boushey, R., Chang, G., et al. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31828cb66c · Cited by 563
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Self-citationEvidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Metadata
- Authors
- Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Sölétormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., & Diamandis, E. P.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-01
- Volume
- 54
- Issue
- 12
- Pages
- e11-e79
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2099052946
- Cited by
- 1,129
- References
- 416
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.